New Delhi metallo-β-lactamase (NDM) is a key subtype of Ambler class B metallo-carbapenemases. It was first identified in clinical antibiotic-resistant isolates from New Delhi, India, in 2009, and is now one of the most high-risk carbapenemases of global concern in clinical resistance surveillance and control.

AccuSift offers high-performance monoclonal antibody pairs against New Delhi metallo-β-lactamase (NDM). Designed for IVD kit development (lateral flow, chemiluminescence, ELISA, POCT), these antibodies deliver excellent batch-to-batch consistency, high affinity, and high specificity to enable rapid detection.

Source: Mouse

Purity: ≥90%

Recommended pair: (Coating) / (Conjugate)

Storage: Long-term: ≤ –20 °C; Short-term: 2–8 °C. Shipped on ice packs.